Jordanian Drug Maker Buys Baxter Injectable Business, Becomes Second Largest In U.S.

Fast-growing Jordanian drug maker Hikma will acquire Baxter Healthcare's U.S. generic injectables business for $112 million. The acquisition doubles Hikma's injectables business and bolsters the company to the No. 2 position in the U.S. market with a projected market share of more than 15 percent. It also solidifies Hikma's leading position in the Middle East and North African (MENA) market, one of the rapidly growing "pharmerging" markets in the world